Lp(a)-Lowering Pelacarsen Shows Huge Disconnect With Cardiovascular Outcomes
(MedPage Today) -- Lowering lipoprotein(a), or Lp(a), did not translate into better cardiovascular outcomes in a secondary prevention population, at least not with pelacarsen in the Lp(a) HORIZON trial. Among people with elevated lipoprotein(a...
We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.